Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 LN-145 in recurrent, metastatic, or persistent cervical carcinoma
NL-OMON53011Phase 2Recruiting
- Sponsor
- Iovance Biotherapeutics
- Start
- Jul 2018
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of LN-145 in Cervical Cancer (CC) (5 cohorts), sponsored by Iovance Biotherapeutics. Primary endpoint: Objective response rate. Started Jul 2018; status: recruiting.
02
Drugs
LN-145
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NL-OMON53011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53011.